Clinical trials: Impairment
Hearing Impairment, Sensorineural
Cochlear Response Telemetry and Hearing Preservation
The main purpose of this study is to monitor the response from the cochlea as the electrode is inserted during the operation to receive a cochlear implant.
- Trial name
- CREST (NCT03134989)
- Testing
- Cochlear implant
- Where
- Argentina
- Volunteers
- 80 people
- Sponsor
- Cochlear
Renal Impairment, Multiple Myeloma
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
This was a multicenter study of the pharmacokinetics (PK) of melphalan during treatment with melflufen and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) and impaired renal function.
- Trial name
- BRIDGE (NCT03639610)
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Czechia, Greece and 1 more
- Volunteers
- 35 people
- Sponsor
- Oncopeptides AB
Heart Failure, Congestive
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy
To evaluate the effect of KW-3902IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function, and on the proportion of deaths or rehospitalizations for heart failure or worsening…
- Trial name
- REACH UP (NCT00443690)
- Testing
- rolofylline
- Volunteers
- 480 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Healthy Subjects, Renal Impairments
Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients
This is a human pharmacology, single-dose study to investigate the pharmacokinetics of orally administered Levetiracetam (LEV) in Japanese subjects with normal renal function and in Japanese subjects with various degrees of…
- Trial name
- NCT01491113
- Testing
- Levetiracetam 250 mg, Levetiracetam 500 mg
- Where
- 2 sites in Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Muscle Damage, Muscle Strength
HIFEM and Radiofrequency for Muscular System Function Improvement
The goal of this clinical trial is to investigate the effect of the BTL-899M device on muscular system function in adult subjects seeking treatment for improving their muscular system function in the lower extremities.
- Conditions
- Muscle Damage, Muscle Strength, Muscle Weakness
- Trial name
- NCT06703749
- Testing
- Treatment with BTL-899M, Treatment with BTL-899M with intensities below therapeutic threshold
- Where
- 3 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Renal Impairment After Cardiac Surgery, Renal Impairment
Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes
Patients with renal insufficiency who undergo cardiac surgery with cardiopulmonary bypass (CPB) are at significant risk for exacerbation of renal dysfunction postoperatively.
- Conditions
- Renal Impairment After Cardiac Surgery, Renal Impairment, Acute Kidney Injury
- Trial name
- GRADIENT (NCT07017933)
- Testing
- Renal assist device
- Where
- 7 sites in United States, Poland
- Volunteers
- 124 people
- Sponsor
- 3ive Labs
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Impairment, Healthy
A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
The purpose of this study is to evaluate the pharmacokinetics of a single dose of intranasally administered esketamine in participants with impaired renal function when compared to participants with normal renal function.
- Trial name
- NCT02606084
- Testing
- Esketamine
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy, Hepatic Impairment
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
The purpose of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calderasib levels in the body when it is given to participants with hepatic (liver)…
- Trial name
- NCT07219550
- Testing
- Calderasib
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatic Function Abnormal, Healthy Volunteers
A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)
This is a single-dose study to assess the effect of mild or moderate Hepatic Impairment (HI) on the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the safety and tolerability of rilzabrutinib in subjects with HI.
- Trial name
- NCT06444204
- Testing
- Rilzabrutinib
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Principia Biopharma, a Sanofi Company
Gait Impairment Due to Mild/Moderate Multiple Sclerosis (MS)
A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS)
PoNS therapy is a rehabilitation program that uses the PoNS device in conjunction with individualized physical exercise. This is an outcome research open label observational interventional multi-center study investigating the…
- Trial name
- PoNSTEP (NCT05437276)
- Testing
- PoNS®
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Helius Medical Inc
Impaired Hepatic Function
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities.
- Trial name
- NCT07682818
- Testing
- Petrelintide
- Where
- 3 sites in Poland, Slovakia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Stroke
Evaluating Neuroprotection in Aneurysm Coiling Therapy
This is a randomized, double-blind, placebo-controlled, single-dose, design investigating the safety, tolerability and efficacy of NA-1, a peptide designed to reduce ischemic brain damage.
- Trial name
- ENACT (NCT00728182)
- Testing
- NA-1
- Where
- 14 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- NoNO Inc.
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Hearing Impairment, Sensorineural
A Feasibility Study Evaluating the Performance of Focused Multipolar Stimulation and Sound Coding in Adults.
The purpose of this early feasibility study is to explore several facets of hearing performance of Focused Multipolar stimulation in adult cochlear implant users.
- Trial name
- SASC (NCT05641155)
- Testing
- Focused Multipolar Stimulation (FMS) strategy
- Where
- 5 sites in United States, Belgium
- Volunteers
- 18 people
- Sponsor
- Cochlear
Memory Loss
The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)
To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.
- Trial name
- NCT00293176
- Testing
- Donepezil Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 821 people
- Sponsor
- Eisai Inc.
Major Depressive Disorder, MDD
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Major Depressive Disorder, MDD, Cognitive Impairment
- Trial name
- NCT05657691
- Testing
- Xanamem™
- Where
- 12 sites in Australia, United Kingdom
- Volunteers
- 167 people
- Sponsor
- Actinogen Medical
Healthy
PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function
The primary objective of this study is to evaluate the potential effect of renal impairment on the systemic pharmacokinetics of acute Intranasal RX0041-002.
- Trial name
- NCT02775955
- Testing
- RX0041
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pharmaceutical Project Solutions, Inc.
Diabetic Retinopathy
Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
The purpose of this study was to demonstrate that the change of best corrected visual acuity (BCVA) was comparable in patients treated with ranibizumab at the discretion of the investigator vs.
- Trial name
- DIVERSE (NCT02366468)
- Testing
- ranibizumab 0.5 mg
- Where
- 30 sites in Germany
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Renal Impairment
A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of pasireotide,the PK of pasireotide in subjects with different degrees of renal impairment.
- Trial name
- NCT01578928
- Testing
- SOM230
- Where
- 2 sites in Germany, South Africa
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.